April 10th, the seminar “Inheritance and Innovation of Chinese Materia Medica, Medicine Innovation and Regulation”, organized by School of Pharmaceutical Sciences of Tsinghua University, was successfully held at Tsinghua Main Building. The Seminar aims to encourage the development of Chinese Materia Medica and Regulatory Science, cultivate future leaders, thereby promoting the innovation of pharmaceutical industry.
This event brought together attendees from the FDA, National Health Commission, CFDA, State Administration of Traditional Chinese Medicine, Beijing Municipal Commission of Health and Family Planning, Beijing Food and Drug Administration, Chinese Academy of Engineering, Chinese Academy of Sciences, related universities as well as pharmaceutical enterprises.
Mingli Shao, former Director of the CFDA, Xianze Sun, former Deputy Director of the CFDA and Director of the Chinese Pharmaceutical Association, Dequan Ren, former Deputy Director of the CFDA and former Deputy Director of the State Administration of Traditional Chinese Medicine, and Academician Kaixian Chen attended the Seminar with opening speeches. They pointed out that The Outline of the Healthy China 2030 Plan and The Outline of the Strategic Plan on the Development of Traditional Chinese Medicine (2016-2030) have both set out a series of tasks and measures to implement the construction of a healthier China, clarified the status of drug innovation and development in the contemporary health service system. In this context, Tsinghua University ought to actively respond to the national strategic demands and shoulder the responsibility, carry out theoretical exploration and research, and advance the development of Chinese Materia Medica and Regulatory.
Following the seminar, related leaders and experts carried out further discussions on the topics of “Opportunities and Challenges of Chinese Materia Medica”, “New Drug Regulatory Concept and Model”, and “New Technologies and Methods of Scientific Regulation”.
